Anthem Inc

Most Recent

  • uploads///crash _
    Consumer

    Goldman Sachs: Trade War Boosts Risk of Recession

    Goldman Sachs (GS) has cut its Q4 growth forecast by 20 basis points. It now foresees the trade war impacting growth more than it previously forecast.

    By Anuradha Garg
  • uploads///adult career clipboard
    Company & Industry Overviews

    This Rebate Decision Saw Health Insurers Soar Yesterday

    On Thursday, the Trump administration announced the withdrawal of the proposal to abolish rebates paid to pharmacy benefit managers by drugmakers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ANTM or CI: Comparing Cash Flows and Capital Investments in 2019

    Analysts expect Cigna’s (CI) operating cash flows to be $8.01 billion, $9.08 billion, and $9.69 billion, respectively, in 2019, 2020, and 2021.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ANTM or CI: Comparing Their Operating Expenses in 2019

    On its fourth-quarter earnings conference call, Cigna (CI) guided for a 2019 medical care ratio in the range of 80.5%–81.5%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ANTM or CI: Comparing Their Earnings Growth in 2019

    In its fourth-quarter earnings press release, Anthem (ANTM) guided for 2019 GAAP (generally accepted accounting principles) EPS of more than $18.00.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ANTM or CI: Comparing Their Revenue Growth in 2019

    In its fourth-quarter earnings press release, Anthem (ANTM) guided for 2019 operating revenue of $100 billion, a YoY (year-over-year) rise of $8.7 billion.

    By Margaret Patrick
  • uploads///computer _
    Company & Industry Overviews

    What Are Analysts Recommending for ANTM and CI?

    On April 12, Anthem (ANTM) closed at $252.85, 8.48% lower than its previous closing price.

    By Margaret Patrick
  • uploads///Express
    Company & Industry Overviews

    Express Scripts Holding Stock Has Risen 36% in 2018

    On November 29, Express Scripts Holding’s stock price closed at $101.22, which is ~5% growth from the close of $96.81 on November 23.

    By Daniel Collins
  • uploads///rawpixel  unsplash
    Earnings Report

    UNH Stock Up 4.1% on Solid Q3 2018 Results, View Up

    UnitedHealth Group (UNH) released its Q3 2018 earnings today. UNH reported sales of $56.6 billion, up ~12.4% on a year-over-year basis.

    By Sarah Collins
  • uploads///family __
    Earnings Report

    Analyst Ratings for UnitedHealth before Q3 2018 Earnings

    Of the 24 analysts covering UNH stock, ten have recommended a “strong buy,” and 13 have recommended a “buy.”

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Jefferies Raised Its Target Price on UNH Stock: What’s the Outlook?

    UnitedHealth Group (UNH) is one of the largest Fortune 500 companies.

    By Sarah Collins
  • uploads///business _
    Healthcare

    Wall Street Expects 9% Upside Potential for UnitedHealth Stock

    As of September 24, ten of the 24 analysts covering UNH stock have given it a “strong buy” recommendation.

    By Sarah Collins
  • uploads///capital plan
    Company & Industry Overviews

    UnitedHealth Group Goes Ex-Dividend Today

    UnitedHealth Group (UNH) has announced that its board of directors has authorized a cash dividend of $0.90 per share.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Analysts Raise Target Prices on UNH Stock in September

    Of the 23 analysts covering UNH stock, all of them have “buy” or “strong buy” recommendations for UnitedHealth Group.

    By Sarah Collins
  • uploads///family insurance _
    Company & Industry Overviews

    UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date

    UnitedHealth Group (UNH) stock registered its 52-week high of $270.17 last week on August 30.

    By Sarah Collins
  • uploads///business _
    Earnings Report

    UnitedHealth Group Reports Q2 2018 Earnings, Stock Down 1.9%

    Today, UnitedHealth Group (UNH) reported its earnings results for the second quarter of fiscal 2018. The company reported sales of $56.1 billion, up ~12% on a (year-over-year) basis.

    By Sarah Collins
  • uploads///family _
    Company & Industry Overviews

    UNH’s Stock Price Performance in June

    On June 28, UnitedHealth Group (UNH) ended the trading day at $244.90, ~4.6% lower than its 52-week low of $183.86 reached on July 18, 2017.

    By Sarah Collins
  • uploads///ANTM
    Company & Industry Overviews

    Norfolk Southern: S&P 500’s Top Gainer on April 25

    Norfolk Southern, which is a premier transportation company in the US, was the S&P 500’s top gainer on April 25.

    By Val Kensington
  • uploads///recommendation
    Earnings Report

    Recommendations for UNH Stock after Its 1Q18 Results: All ‘Buy’

    Of the 22 analysts tracking UNH stock on April 19, 50% rated it as a “strong buy,” and the remaining 50% of these analysts rated the company as a “buy.”

    By Sarah Collins
  • uploads///insurance _
    Earnings Report

    UnitedHealth Group Posted Strong 1Q18 Performance

    On April 17, UnitedHealth Group (UNH) reported its 1Q18 earnings results. UNH stock rose ~3.6% from its April 16 closing price.

    By Sarah Collins
  • uploads///
    Company & Industry Overviews

    Amazon’s Healthcare Venture: An Opportunity for Microsoft?

    In the second week of April 2018, St. Jude Children’s Research Hospital announced the launch of the St. Jude Cloud, which it described as the world’s largest public store of pediatric cancer genomics data.

    By Ruchi Gupta
  • uploads///family _
    Earnings Report

    Analysts’ Recommendations for UnitedHealth Group

    UnitedHealth Group is the world’s largest healthcare company in terms of revenue. In fiscal 2017, it generated revenue of $201 billion.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    UnitedHealth Group’s Recent Stock Performance

    On March 14, 2018, UnitedHealth Group (UNH) ended trading at $225.38 per share.

    By Sarah Collins
  • uploads///capital allocation
    Company & Industry Overviews

    UnitedHealth Group’s Dividend Payment of $0.75 Payable March 20

    On February 14, UnitedHealth Group authorized a quarterly dividend payment of $0.75 to shareholders of record on March 9, 2018.

    By Sarah Collins
  • uploads///Graph
    Healthcare

    Cigna Expects to Report Robust Revenue Growth in the Future

    Cigna (CI) has projected its expected annual revenue growth rate in the range of 6%–to 8% from 2017 to 2021, assuming completion of the Express Scripts acquisition.

    By Margaret Patrick
  • uploads///Graph
    Healthcare

    Could Cigna–Express Scripts Deal Be Earnings Accretive in Year 1?

    Cigna (CI) expects the acquisition of Express Scripts to boost the EPS of the combined company in the double digits in the first full year.

    By Margaret Patrick
  • uploads///recommendations
    Earnings Report

    Analysts’ Recommendations for UNH, Pre-4Q17 Earnings Announcement

    Headquartered in Minnesota, Fortune 500 company UnitedHealth Group (UNH) is the world’s largest healthcare company based on revenue, which totaled ~$184 billion for UNH in fiscal 2016.

    By Sarah Collins
  • uploads///Insys priorities
    Company & Industry Overviews

    Insys Has Legal Issues Galore

    In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.

    By Kenneth Smith
  • uploads///STOCK BUYBACKS
    Consumer

    What Led Oracle to Add $12 Billion to Its Share Buyback Program?

    During its fiscal 2Q18 results, Oracle announced that it had added $12 billion to the company’s share buyback program.

    By Anne Shields
  • uploads///Part  Graph
    Company & Industry Overviews

    Healthcare Sector Overview: Week of May 22–26, 2017

    Through May 26, 2017, 83% of healthcare stocks have delivered earnings above analysts’ estimates. About 16% of healthcare stocks have missed analysts’ estimates, while 2% reported earnings in line with analysts’ estimates.

    By Alexis Tate
  • uploads///Graph
    Company & Industry Overviews

    Medicare Business Expected to Drive WellCare Health Plans’ Margin Growth

    In 1Q17, WellCare Health Plans’ (WCG) Medicare Health Plans business reported revenues close to $1.1 billion, which represents year-over-year growth of ~12.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medicaid Business—A Key Revenue Driver for WellCare Health Plans in 2017

    In 1Q17, WellCare Health Plans’ (WCG) Medicaid business reported revenues close to $2.6 billion, which equals year-over-year growth of ~11.8%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Why Anthem’s Benefit Expense Ratio Rose in 1Q17

    Expense guidance for 2017 For full-year 2017, Anthem (ANTM) has projected the medical cost trend for its local group business to fall in the range of 6.5%–7.0%. To learn more about medical cost trends, please see Medical cost trend means rising premiums for health insurance. If Anthem’s actual medical cost trend for full-year 2017 turns out […]

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts’ Recommendations for Anthem in 2017

    Based on the company’s performance in 1Q17, Anthem (ANTM) has increased its 2017 revenue guidance by around $1.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Centene Saw Robust Rise in Medicaid Enrollments in 1Q17

    In 1Q17, around 12.1 million members were enrolled in Centene’s (CNC) various healthcare plans, which is a year-over-year (or YoY) rise of around 600,000 beneficiaries.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Why Centene’s Health Benefit Ratio Improved in 1Q17

    Centene (CNC) has projected its health benefit ratio (or HBR) for the full year 2017 to fall in the range of 87.0% to 87.5%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    OptumRx and OptumInsight May Witness Robust Growth Trends in 2017

    In 1Q17, UnitedHealth Group’s (UNH) Optum business reported $21.2 billion in revenues, which represents year-over-year growth of around 7.9%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group Witnessed Robust Customer Growth in 1Q17

    In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    OptumCare Is a Major Driving Force for UnitedHealth Group in 1Q17

    In 1Q17, UnitedHealth Group’s (UNH) OptumHealth segment served 6 million more people on a year-over-year basis.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Negative Sentiment Will Impact Health Insurance Companies

    The healthcare bill’s failure had a negative impact on investor sentiment for health insurance carriers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    OptumRx Continues to Boost UnitedHealth’s Pharmacy Care Services

    In its bid to control healthcare costs, UnitedHealth Group’s (UNH) OptumRx segment has been actively deploying data analytics across its Optum platform.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will UnitedHealth’s Optum One Improve Decision-Making in 2017?

    UnitedHealth Group’s (UNH) Optum One is being used by about 700 hospitals and 7,000 medical clinics, which together cover about 140,000 healthcare providers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Optum360: Will It Become UnitedHealth’s Key Growth Driver?

    Optum360, UnitedHealth Group’s (UNH) hospital revenue cycle management solution, is expected to reach $60.0 billion in billings for clients and partner organizations.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    UnitedHealth Group: Robust Revenue Expected

    Wall Street analysts have projected UnitedHealth Group’s 2016 revenues to be about $183.9 billion, which is a YoY growth of 17.1%.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Is Mylan’s Generics Segment Doing?

    Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for UNH ahead of 2Q16 Earnings?

    The consensus 12-month target price for UnitedHealth Group’s stock is ~$152.60, which represents a rise of 8.8% from the stock’s closing price of $140.30 on July 11, 2016.

    By Margaret Patrick
  • uploads///STRZA LGF library
    Healthcare

    Parsing the Starz-Lions Gate MAE Clause, Part 3

    If the merger caused cable providers to drop Starz because they didn’t want to work with Lions Gate, it wouldn’t be a MAE (material adverse effect).

    By Brent Nyitray, CFA, MBA
  • uploads///STRZA LGF shareholder value
    Healthcare

    Parsing the Starz-Lions Gate MAE Clause, Part 2

    According to the MAE (material adverse effect) clause of the Starz-Lions Gate deal, legislation that limits intellectual property protection wouldn’t be considered a MAE.

    By Brent Nyitray, CFA, MBA
  • uploads///STRZA LGF benefits of pairing
    Healthcare

    Parsing the Starz-Lions Gate MAE Clause, Part 1

    In the merger deal between Lions Gate Entertainment (LGF) and Starz (STRZA), the MAE (material adverse effect) clause lays out the circumstances under which either party can back out of the transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG transformative combination
    Miscellaneous

    The Amsurg-Envision Material Adverse Effect Clause: Part 2

    In this part of the series, we’ll look at the MAE clause of the Amsurg (AMSG) merger agreement with Envision Healthcare (EVHC) and how Amsurg could back out of the deal.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG best in class
    Miscellaneous

    What’s the Main Regulatory Risk of the Envision-Amsurg Deal?

    In the risk arbitrage world, a 2.8% annualized return is pretty small. There’s some overlap that could concern regulators. The main risk would be the timing risk.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG combination
    Miscellaneous

    Can the Amsurg-Envision Transaction Get Antitrust Approval?

    In the case of Amsurg (AMSG) and Envision (EVHC), the gating item will depend on how closely antitrust regulators look at the transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG summary terms
    Miscellaneous

    What’s the Rationale for the Amsurg-Envision Merger?

    Amsurg and Envision are merging. Envision shareholders will receive 0.334 shares of Amsurg stock for each share of Envision they hold.

    By Brent Nyitray, CFA, MBA
  • uploads///EVHC AMSG spread
    Miscellaneous

    Amsurg and Envision Merge to Form a Healthcare Services Juggernaut

    On June 15, Amsurg (AMSG) and Envision (EVHC) announced a merger. Envision will hold 53% of the new company and Amsurg will hold 47%.

    By Brent Nyitray, CFA, MBA
  • uploads///TLN RVS TLN basics
    Miscellaneous

    Why Is the Talen-Riverstone Spread Trading Tight?

    The merger spread is trading at 1.1% gross—about 1.9% annualized. Even in an unusually low interest rate environment, that’s a low return.

    By Brent Nyitray, CFA, MBA
  • uploads///TLN RVS downside
    Miscellaneous

    What’s the Risk-Reward Ratio for the Talen Transaction?

    If the Talen deal closes as advertised, you will make about $0.15. If the deal breaks, you will lose $1.85 per share. So, the risk-reward ratio is just over 12:1.

    By Brent Nyitray, CFA, MBA
  • uploads///TLN RVS investment thesis
    Miscellaneous

    Why Going Private Is a Good Result for Talen

    Given Talen’s close proximity to the Marcellus Shale region, it faces competition from other electricity generating companies that use cheap natural gas.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE CRM Massive Opportunity
    Miscellaneous

    What’s the Rationale for the Demandware-Salesforce Merger?

    Salesforce.com is paying a pretty penny for Demandware at 11 times its revenue. This gives a good indication of just how much potential growth Salesforce.com sees in the space.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE CRM Key takeaways
    Miscellaneous

    What Does the Demandware-Salesforce Merger Entail?

    Salesforce.com (CRM) is buying e-commerce cloud computing firm Demandware (DWRE) in a $2.8 billion transaction. The merger is structured as a tender offer.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE CRM downside
    Miscellaneous

    What Is the Risk-Reward of the Demandware Deal?

    Demandware (DWRE) was trading at about $48 per share before the deal was announced.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE CRM comps
    Miscellaneous

    Demandware’s Stock Price Hints at a Competing Buyer

    Competitive deals can make your quarter if you’re a merger arbitrage professional.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE CRM enterprise retail
    Miscellaneous

    What Will Arbitrageurs Think of the Demandware Deal?

    Traditionally, arbitrage desks would have a portfolio of 40–50 “safe” transactions, and these make up the bread and butter of their returns.

    By Brent Nyitray, CFA, MBA
  • uploads///DWRE DRM spread
    Miscellaneous

    Salesforce Buys Demandware to Increase Growth

    On June 1, Salesforce.com (CRM) announced it was buying Demandware (DWRE) in a $2.8 billion transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///MON BAY MON opportunity
    Miscellaneous

    Anticipated Steps for the Monsanto-Bayer Merger

    Bayer AG sent a bear hug letter to Monsanto (MON) publicly stating its intent to purchase the company for $122 per share in cash.

    By Brent Nyitray, CFA, MBA
  • uploads///MON BAY crop protection
    Miscellaneous

    What’s the Rationale for the Bayer-Monsanto Deal?

    In the Monsanto-Bayer deal, Bayer’s shareholders should expect to see mid-single-digit accretion to core EPS (earnings per share) in the first year and double-digit accretion thereafter.

    By Brent Nyitray, CFA, MBA
  • uploads///MON BAY spread
    Miscellaneous

    Bayer Sends a Bear Hug to Monsanto

    On May 23, Bayer confirmed it was interested in buying Monsanto for $122 in cash per share, or an aggregate value of $62 billion.

    By Brent Nyitray, CFA, MBA
  • uploads///STJ ABT STJ basics
    Miscellaneous

    Will Professional Arbitrageurs Set Up the St. Jude-Abbott Merger?

    This transaction is a classic merger arb core position. There’s always the possibility of someone coming in over the top for St. Jude Medical (STJ).

    By Brent Nyitray, CFA, MBA
  • uploads///STJ ABT spread
    Miscellaneous

    Abbott Buys St. Jude Medical for $85 per Share in Cash and Stock

    On April 28, Abbott Labs and St. Jude Medical announced an agreement where Abbott will buy St. Jude for $30 billion in cash, stock, and assumed debt.

    By Brent Nyitray, CFA, MBA
  • uploads///BHI HAL arbitrage spread
    Miscellaneous

    Baker Hughes and Halliburton Terminate Their Merger

    On May 1, Baker Hughes (BHI) and Halliburton (HAL) officially terminated their merger agreement. Halliburton will pay Baker Hughes the $3.5 billion reverse termination fee.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    What You’ll Want to Know about Anthem’s Guidance for 2016

    In its 1Q16 conference call, Anthem updated its 2016 revenue guidance to $81 billion–$82 billion—higher than the previous projection by about $1 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Outpatient and Pharmacy Costs May Drive Up UnitedHealth Group’s Medical Costs in 2016

    In 1Q16, UnitedHealth Group witnessed overall medical cost trends in the range of 5.5%–6.5%. This is in line with the 2016 guidance given in December 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Behind OptumHealth’s and OptumInsight’s Strong Revenue Growth in 1Q16

    UnitedHealth Group’s healthcare delivery business, OptumHealth, managed to earn $4 billion revenues in 1Q16, which represents a YoY growth of about 22%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Why UnitedHealth Group Plans to Reduce Its Public Exchange Exposure

    Given the high-risk profile of individual exchange enrollments, UnitedHealth Group has decided to offer plans only on a few public exchanges in 2017.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Drove UnitedHealth Group’s Medicare & Retirement Business in 1Q16?

    UnitedHealthcare’s Medicare & Retirement business reported revenues worth $14.1 billion in 1Q16, which represents a YoY increase of approximately 10%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group’s 1Q16 Earnings Are Out: Here’s What the Conference Said

    UnitedHealth Group (UNH) posted its 1Q16 earnings on April 19. The company registered diluted EPS of $1.81—17% higher than its EPS in 1Q15.

    By Margaret Patrick
  • uploads///HTS NLY HTS highlights
    Miscellaneous

    What Are the Conditions of the Hatteras-Annaly Merger?

    Hatteras has a no-shop provision with a fiduciary out. This means that Hatteras isn’t allowed to solicit other buyers during the pendency of the merger.

    By Brent Nyitray, CFA, MBA
  • uploads///HOT MAR spread
    Miscellaneous

    Why Did Starwood Accept a Better Offer from Marriott?

    On March 21, Starwood and Marriott amended their merger agreement to top Anbang’s offer. The amended merger spread is trading at an annualized return of 1.3%.

    By Brent Nyitray, CFA, MBA
  • uploads///HOT MAR HOT basics
    Miscellaneous

    An Interloper Enters the Starwood-Marriott Deal

    On March 14, Starwood Hotels & Resorts Worldwide (HOT) announced that it received an unsolicited takeover approach from a consortium of investors led by China’s Anbang Insurance Group.

    By Brent Nyitray, CFA, MBA
  • uploads///TFM APO comps
    Miscellaneous

    Could The Fresh Market Deal Become Competitive?

    The $28.50 purchase price was a high premium of over 24% to where The Fresh Market was trading on March 11, 2016—the day before the deal was announced.

    By Brent Nyitray, CFA, MBA
  • uploads///TFM APO EBITDA
    Miscellaneous

    Apollo-The Fresh Market Transaction: What Are the Conditions?

    The Fresh Market has a go-shop provision. It can solicit other bids for the first 21 days. Then, it will be held to the customary no-shop provision with a fiduciary out.

    By Brent Nyitray, CFA, MBA
  • uploads///TFM APO revenues
    Miscellaneous

    What’s the Rationale for The Fresh Market Transaction?

    As with any private equity transaction, the goal is to buy the company, improve its performance, and then sell it back into the marketplace at a higher multiple.

    By Brent Nyitray, CFA, MBA
  • uploads///Chart
    Company & Industry Overviews

    Decoding Humana’s Revenue Stream in 2015

    Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.

    By Mike Benson
  • uploads///Tumi Tumi basics
    Miscellaneous

    Will Arbs Impact the Samsonite-Tumi Deal?

    There’s the possibility of a bidding war. Arbs will probably have a small position in case there’s a bidding war. They will scale in if the spread widens.

    By Brent Nyitray, CFA, MBA
  • uploads///Tumi Comps
    Miscellaneous

    Could the Samsonite-Tumi Merger Get Competitive?

    The $42 purchase price was a high premium of over 33% to where Tumi (TUMI) was trading on March 2, 2016—the day before the deal was announced.

    By Brent Nyitray, CFA, MBA
  • uploads///Tumi Segment
    Miscellaneous

    Can the Samsonite-Tumi Merger Get Antitrust Approval?

    Samsonite will need to file for merger approval under the Hart-Scott-Rodino Antitrust Improvements Act. The companies will need to file for Canadian antitrust approval.

    By Brent Nyitray, CFA, MBA
  • uploads///Tumi Strategic Fit
    Miscellaneous

    What’s the Rationale for the Samsonite-Tumi Transaction?

    Hong Kong-based Samsonite is buying luxury brand Tumi (TUMI) in a $1.8 billion deal. Samsonite is mainly known as a utilitarian luggage company.

    By Brent Nyitray, CFA, MBA
  • uploads///TUmi Spread
    Miscellaneous

    Big Deal: Samsonite Buys Tumi in a $1.8 Billion Deal

    On March 3, Samsonite and Tumi announced that Samsonite will buy Tumi in a $1.8 billion deal. The deal will be a cash transaction set at $26.75 per share.

    By Brent Nyitray, CFA, MBA
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Rose as 52 of Its Holdings Posted Positive Returns

    XLV rose 1.4% on February 22, 2016, as 52 of its holdings posted positive returns. Only four of XLV’s stocks ended in the red.

    By Peter Neil
  • uploads///ITC FTS timeline
    Miscellaneous

    ITC-Fortis Spread: What to Expect from Arbitrageurs

    The ITC (ITC)-Fortis transaction is a utility deal and arbitrageurs tend to avoid them. State regulatory approvals are generally inscrutable.

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FTS downside
    Miscellaneous

    What’s the Risk-Reward Ratio for the ITC-Fortis Deal?

    ITC (ITC) was trading at ~$33 per share before the press reported it was in talks for a sale. If the deal breaks, will ITC’s share price return to its former level?

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FTS strategic rationale
    Miscellaneous

    What’s the Rationale for the ITC-Fortis Merger?

    Fortis (FRTSF) is buying ITC (ITC) in the largest Canadian purchase of a US utility. Fortis intends to sell a 19% stake in order to help finance the transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FRTSF spread
    Miscellaneous

    What Does the ITC-Fortis Merger Mean for Investors?

    On February 9, 2016, Fortis and ITC announced a merger. Fortis is buying ITC in a $6.6 billion deal. Including debt, the deal’s value is $11.2 billion.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    Will Increasing Scale and Diversification Boost Centene’s Revenues?

    After the closure of Centene-Health Net Deal, Centene expects to benefit from increased scale of operations and diversification of revenue base.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Centene’s Hunt for New Growth Opportunities in Existing Markets

    Centene believes that if all its existing markets adopt Medicaid expansion, it would result in 4 million additional members becoming eligible for Medicaid.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Subsidy Eligible Membership Could Mean for Centene’s Public Exchange Revenues

    Centene managed to increase its public exchange membership from 75,000 members in 2015 to 146,000 members in 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Did Centene’s Geographical Diversification Strategy Boosts Pan out for Its 4Q15 Earnings?

    Centene posted its 4Q15 and 2015 earnings on February 09 and reported diluted operating EPS attributable to common shareholders of about $2.89 for 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Cigna’s Earnings Margin Falls due to Increased Medical Costs

    In 4Q15, Cigna’s EBITDA (earnings before interest, tax, depreciation, and amortization) margin fell year-over-year (or YoY) by 0.7% to reach 9.7%.

    By Margaret Patrick
  • uploads///ALR ABT ABT basics
    Miscellaneous

    What You Need to Know about the Abbott Labs Side of the Alere-Abbott Merger

    Abbott Laboratories is a leading pharmaceutical company that also makes diagnostic products, nutritional products, and vascular products.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    Anthem’s Medical Care Ratio Jumped in 4Q15

    In 4Q15, Anthem’s medical care ratio, a ratio of medical costs against premium revenues, rose by 2.5% YoY. Its medical care ratio for fiscal 2015 was 83.3%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Anthem Expects to Generate Substantial Savings from Pharmaceutical Pricing in 2016

    Anthem plans to negotiate pharmaceutical pricing with Express Scripts in an effort to improve affordability, secure more members, and enroll new customers.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.